Publications and Papers

Home » Research » Publications and Papers
Publications and Papers2023-04-03T10:10:19+10:00

MIA researchers play a significant role in expanding world knowledge about melanoma. We’ve compiled a list of all recent publications so you can access all MIA research papers in one place.

Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial).

2023-05-15T22:05:53+10:00March 29th, 2023|

Yan MK, Cust AE, Soyer HP, Janda M, Loewe K, Byars G, Fishburn P, White P, Mahumud RA, Saw RPM, Herschtal A, Fernandez-Penas P, Guitera P, Morton RL, Kelly J, Wolfe R, Mar VJ.  Trials. 2023 Mar 29;24(1):236. doi: 10.1186/s13063-023-07203-5. PMID: 36991460; PMCID: PMC10061902

|

REPLY to MS#JAAD-D-23-00002R1.

2023-05-15T20:05:54+10:00March 17th, 2023|

El Sharouni MA, Lo SN, Scolyer RA, van Gils CH, Thompson JF. J Am Acad Dermatol. 2023 Mar 17:S0190-9622(23)00440-1. doi: 10.1016/j.jaad.2023.03.008. Epub ahead of print. PMID: 36935017.

|

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.

2023-05-14T19:44:01+10:00March 15th, 2023|

Reijers ILM, Rao D, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, Spillane AJ, Klop WMC, Broeks A, Bosch LJW, Lopez-Yurda M, van Houdt WJ, Rawson RV, Grijpink-Ongering LG, Gonzalez M, Cornelissen S, Bouwman J, Sanders J, Plasmeijer E, Elshot YS, Scolyer RA, van de Wiel BA, Peeper DS, van Akkooi ACJ, Long GV, Blank CU. J Exp Med. 2023 May 1;220(5):e20221952. doi: 10.1084/jem.20221952. Epub 2023 Mar 15. PMID: 36920329; PMCID: PMC10037109.

|

MC1R ‘r’ allele does not increase melanoma risk in MITF E318K carriers.

2023-05-15T20:42:49+10:00March 5th, 2023|

Wallingford CK, Demeshko A, Krishnankutty Krishnakripa A, Smit DJ, Duffy DL, Betz-Stablein B, Pflugfelder A, Jagirdar K, Holland E, Mann GJ, Primiero CA, Yanes T, Malvehy J, Badenas C, Carrera C, Aguilera P, Olsen CM, Ward SV, Haass NK, Sturm RA, Puig S, Whiteman DC, Law MH, Cust AE, Potrony M, Soyer HP, McInerney-Leo AM. Br J Dermatol. 2023 Mar 5:ljad041. doi: 10.1093/bjd/ljad041. Epub ahead of print. PMID: 36879448.

|

Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.

2023-05-14T17:39:43+10:00March 2nd, 2023|

Allen NC, Martin AJ, Snaidr VA, Eggins R, Chong AH, Fernandéz-Peñas P, Gin D, Sidhu S, Paddon VL, Banney LA, Lim A, Upjohn E, Schaider H, Ganhewa AD, Nguyen J, McKenzie CA, Prakash S, McLean C, Lochhead A, Ibbetson J, Dettrick A, Landgren A, Allnutt KJ, Allison C, Davenport RB, Mumford BP, Wong B, Stagg B, Tedman A, Gribbin H, Edwards HA, De Rosa N, Stewart T, Doolan BJ, Kok Y, Simpson K, Low ZM, Kovitwanichkanont T, Scolyer RA, Dhillon HM, Vardy JL, Chadban SJ, Bowen DG, Chen AC, Damian DL. N Engl J Med. 2023 Mar 2;388(9):804-812. doi: 10.1056/NEJMoa2203086. PMID: 36856616.

|

Clinical features and outcomes of cardiac involvement in patients with cancer treated with immune checkpoint inhibitors.

2023-05-14T19:23:51+10:00March 1st, 2023|
Sarah Abou Alaiwi, Amin Nassar, Talal Zarif, Edward El-Am, Ryan Denu, Walid Macaron, Carmel Malvar, Alessio Cortellini, James Korolewicz, Paul Sackstein, Frank Aboubakar Nana, Rachel Woodford, Georgina V. Long, Jennifer Kwan, Shirly Grynberg, Ronnie Shapira, Mercedes Herrera-Juárez, Simone Foderaro, Alexi Vasbinder, Aarti Asnani, Ankita Tandon, Salim Hayek, Tomas G. Neilan, Toni Choueiri, and Abdul-Rafeh Naqash.  J Am Coll Cardiol. 2023 Mar, 81 (8_Supplement) 2338.https://doi.org/10.1016/S0735-1097(23)02782-1
|

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.

2023-05-14T17:31:03+10:00February 24th, 2023|

Linardou H, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Mathias CC, Choo SP, Dent R, Felip E, Furness AJS, Garassino MC, Garralda E, Konsoulova-Kirova A, Letsch A, Menzies AM, Mukherji D, Peters S, Sessa C, Tsang J, Yang JC, Garrido P. ESMO Open. 2023 Feb 24;8(2):100781. doi: 10.1016/j.esmoop.2023.100781. Epub ahead of print. PMID: 36842299.

|

Reply to A. Mangla and E. Hindié.

2023-05-15T13:34:42+10:00February 20th, 2023|

Moncrieff MD, Sondak VK, Thompson JF, Zager JS.  J Clin Oncol. 2023 Feb 20;41(6):1326-1327. doi: 10.1200/JCO.22.02218. Epub 2022 Dec 1. PMID: 36455171.

|

Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy.

2023-05-15T20:22:46+10:00February 15th, 2023|

Lee H, Ferguson AL, Quek C, Vergara IA, Pires daSilva I, Allen R, Gide TN, Conway JW, Koufariotis LT, Hayward NK, Waddell N, Carlino MS, Menzies AM, Saw RPM, Shklovskaya E, Rizos H, Lo S, Scolyer RA, Long GV, Palendira U, Wilmott JS. Clin Cancer Res. 2023 Feb 15:CCR-22-2657. doi: 10.1158/1078-0432.CCR-22-2657. Epub ahead of print. PMID: 36790412.

|

Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial.

2023-05-14T17:00:47+10:00February 15th, 2023|

Bartula I, Anh D. Tran, Anna K. Nowak, Tasnia Ahmed, Rachael L. Morton, Bryan H. Burmeister, Kari Dolven-Jacobsen, Jenny Nobes, John F. Thompson, Gerald B. Fogarty, Serigne N Lo, Angela M. Hong. Clinical and Translational Radiation Oncology,
2. 2023, 100597, ISSN 2405-6308, https://doi.org/10.1016/j.ctro.2023.100597

|

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

2023-05-14T16:06:01+10:00February 13th, 2023|

Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob J-J.  Journal of Clinical Oncology, (Feb 13 2023): JCO.22.02072, doi:10.1200/jco.22.02072.

|

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

2023-05-15T21:32:50+10:00February 7th, 2023|

Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, van Akkooi ACJ, Flaherty KT, Boland GM, Peeper DS.  Nat Commun. 2023 Feb 7;14(1):672. doi: 10.1038/s41467-023-35852-2. Erratum for: Nat Commun. 2020 Aug 7;11(1):3946. PMID: 36750559; PMCID: PMC9905532.

|

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.

2023-05-14T16:54:39+10:00February 1st, 2023|

Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Clin Cancer Res, 29, no. 3, (Feb 1 2023): 521-31, doi:10.1158/1078-0432.Ccr-22-2581

|

IFNγ signaling sensitizes melanoma cells to BH3 Mimetics.

2023-05-14T16:40:18+10:00February 1st, 2023|

Ming Z, Lim SY, Stewart A, Pedersen B, Shklovskaya E, Menzies AM, Carlino MS, Kefford RF, Lee JH, Scolyer RA, Long GV, Rizos H.  Journal of Investigative Dermatology, (Feb 01 2023), doi:https://doi.org/10.1016/j.jid.2023.01.017.

|

ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

2023-05-15T21:52:04+10:00January 30th, 2023|

Blankenstein SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, van Akkooi ACJ. Ann Surg Oncol. 2023 Jan;30(1):587-588. doi: 10.1245/s10434-022-12719-2. PMID: 36319872.

|

Association of Germline Variants in Telomere Maintenance Genes (POT1, TERF2IP, ACD, TERT) with Spitzoid Morphology in Familial Melanoma: A Multi-Center Case Series.

2023-05-14T16:36:38+10:00January 28th, 2023|

Goldstein AM, Qin R, Chu EY, Elder DE, Massi D, Adams DJ, Harms PW, Robles-Espinoza CD, Newton-Bishop JA, Bishop DT, Harland M, Holland EA, Cust AE, Schmid H, Mann GJ, Puig S, Potrony M, Alos L, Nagore E, Millán-Esteban D, Hayward NK, Broit N, Palmer JM, Nathan V, Berry EG, Astiazaran-Symonds E, Yang XR, Tucker MA, Landi MT, Pfeiffer RM, Sargen MR. JAAD International, (Jan 28 2023), doi:10.1016/j.jdin.2023.01.013.

|

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

2023-05-14T16:01:42+10:00January 18th, 2023|

Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch’ng S, van Thienen JV, Mallo H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, van der Wal A, Bruining A, van de Wiel BA, Scolyer RA, Haanen J, Schumacher TN, van Akkooi ACJ, Long GV, Blank CU.  Ann Oncol, (Jan 18 2023), doi:10.1016/j.annonc.2023.01.004

|

Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.

2023-05-14T15:15:25+10:00January 10th, 2023|

Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA.  Nature, (Jan 10 2023), doi:10.1038/s41586-022-05632-x.

 

|

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

2023-05-14T11:12:23+10:00January 9th, 2023|

Wong SK, Blum SM, Sun X, Pires Da Silva I, Zubiri L, Ye F, Bai K, Zhang K, Ugurel S, Zimmer L, Livingstone E, Schadendorf D, Serra-Bellver P, Muñoz-Couselo E, Ortiz C, Lostes J, Huertas RM, Arance A, Pickering L, Long GV, Carlino MS, Buchbinder EI, Vázquez-Cortés L, Jara-Casas D, Márquez-Rodas I, González-Espinoza IR, Balko JM, Menzies AM, Sullivan RJ, Johnson DB. European Journal of Cancer, 2022, ISSN 0959-8049

|

Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement

2023-04-03T10:14:47+10:00January 3rd, 2023|

Barnhill RL, Elder DE, Piepkorn MW, Knezevich SR, Reisch LM, Eguchi MM, Bastian BC, Blokx W, Bosenberg M, Busam KJ, Carr R, Cochran A, Cook MG, Duncan LM, Elenitsas R, de la Fouchardière A, Gerami P, Johansson I, Ko J, Landman G, Lazar AJ, Lowe L, Massi D, Messina J, Mihic-Probst D, Parker DC, Schmidt B, Shea CR, Scolyer RA, Tetzlaff M, Xu X, Yeh I, Zembowicz A, Elmore JG.  JAMA Netw Open. 2023 Jan 3;6(1):e2250613. doi: 10.1001/jamanetworkopen.2022.50613. PMID: 36630138.

|

Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study.

2023-05-15T13:41:18+10:00December 20th, 2022|

Dempsey K, Saw R, Bartula I, Lo S, Lawn C, Pennington T, Spillane A, Boyle F, Dong S, Dieng M, Milne D, Seaman L, Saks D, Lai-Kwon J, Thompson JR, Morton R. BMJ Open. 2022 Dec 20;12(12):e066852. doi: 10.1136/bmjopen-2022-066852. PMID: 36600423; PMCID: PMC9772660.

 

|

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

2023-01-21T22:32:20+11:00December 8th, 2022|

Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, Stoltenborg Granhøj J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Retèl VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, Hölmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233. PMID: 36477031.

|

Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.

2023-01-21T22:57:07+11:00December 7th, 2022|

Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Clin Cancer Res. 2022 Dec 7:CCR-22-2581. doi: 10.1158/1078-0432.CCR-22-2581. Epub ahead of print. PMID: 36477181.

|

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: long term outcomes.

2022-11-20T14:37:39+11:00November 9th, 2022|

J. Lee, T. Ahmed, A. Maurichi, L. Di Guardo, A.M. Stagno, L. Warburton, A. Taylor, E. Livingstone, S. Rehman, A. Khattak, K. Kahler, V. Vanella, V. Atkinson, M. Millward, D. Schadendorf, D.B. Johnson, P.A. Ascierto, A. Hauschild, S.N. Lo, G.V. Long, A.M. Menzies, M.S. Carlino. European Journal of Cancer, 2022, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2022.11.009.

|

Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study.

2022-11-20T14:01:27+11:00October 25th, 2022|

Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, Stradella A, Long GV, Spreafico A, Shimizu T, Steeghs N, Luke JJ, McWhirter SM, Müller T, Nair N, Lewis N, Chen X, Bean A, Kattenhorn L, Pelletier M, Sandhu S. Clin Cancer Res. 2022 Oct 25:CCR-22-2235. doi: 10.1158/1078-0432.CCR-22-2235. Epub ahead of print. PMID: 36282874.

|

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

2022-11-20T09:47:33+11:00October 18th, 2022|

Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob J-J, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA.  The Lancet Oncology, (Oct 18 2022)

|

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

2022-11-20T13:34:01+11:00October 7th, 2022|

Serra-Bellver P, Versluis JM, Oberoi HK, Zhou C, Slattery TD, Khan Y, Patrinely JR, Pires da Silva I, Martínez-Vila C, Cook N, Graham DM, Carlino MS, Menzies AM, Arance AM, Johnson DB, Long GV, Pickering L, Larkin JMG, Blank CU, Lorigan P. Eur J Cancer. 2022 Oct 7;176:121-132. doi: 10.1016/j.ejca.2022.09.004. Epub ahead of print. PMID: 36215945.

 

|

Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

2022-11-20T09:27:24+11:00October 6th, 2022|

Blankenstein SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, van Akkooi ACJ. Ann Surg Oncol. 2022 Oct 6. doi: 10.1245/s10434-022-12600-2. Epub ahead of print. PMID: 36203067.

|

Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.

2022-11-19T22:44:45+11:00October 3rd, 2022|

Muhammad A. Khattak, Jason J. Luke, Georgina V. Long, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Caroline Robert, Jean-Jacques Grob, Luis de la Cruz Merino, Michele Del Vecchio, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, Matteo S. Carlino, Peter Mohr, Federica De Galitiis, Merrick I. Ross, Zeynep Eroglu, Ke Chen, Ruixuan Jiang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M.M. Eggermont, John M. Kirkwood. European Journal of Cancer, 2022, ISSN 0959-8049

|

Obesity is associated with altered tumor metabolism in metastatic melanoma.

2022-11-19T22:24:52+11:00September 27th, 2022|

Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Gopal Y N V, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Clin Cancer Res. 2022 Sep 27:CCR-22-2661. doi: 10.1158/1078-0432.CCR-22-2661. Epub ahead of print. PMID: 36166093.

|

Hypoxia controls the glycome signature and galectin-8 – ligand axis to promote pro-tumorigenic properties of metastatic melanoma.

2022-11-19T22:31:02+11:00September 26th, 2022|

Chakraborty A, Perez M, Carroll JD, Antonopoulos A, Dell A, Ortega L, Mohammed NBB, Wells M, Staudinger C, Griswold A, Chandler KB, Marrero C, Jimenez R, Tani Y, Wilmott JS, Thompson JF, Wang W, Sackstein R, Scolyer RA, Murphy GF, Haslam SM, Dimitroff CJ. J Invest Dermatol. 2022 Sep 26:S0022-202X(22)01931-5. doi: 10.1016/j.jid.2022.07.033. Epub ahead of print. PMID: 36174713.

|

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).

2022-11-19T22:17:24+11:00September 26th, 2022|

Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV. J Clin Oncol. 2022 Sep 26:JCO2200533. doi: 10.1200/JCO.22.00533. Epub ahead of print. PMID: 36162037.

|

Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.

2022-11-19T22:01:59+11:00September 23rd, 2022|

Smith JL, Menzies AM, Cohen JV, Mut-Lloret M, Ozgun A, Spain L, Park J, Quach HT, Pallan L, McQuade J, Feng S, Sandhu S, Atkinson V, Tsai K, Long GV, Larkin J, Eroglu Z, Johnson DB, Sullivan R, Herkes GK, Henderson A, Carlino MS. Melanoma Res. 2022 Sep 23. doi: 10.1097/CMR.0000000000000825. Epub ahead of print. PMID: 36164923.

|

Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.

2022-11-19T22:37:15+11:00September 22nd, 2022|

Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. CEur J Cancer. 2022 Sep 22;175:224-235. doi: 10.1016/j.ejca.2022.08.009. Epub ahead of print. PMID: 36155116.

 

|

Comparative genomics provides etiological and biological insights into melanoma subtypes

2022-10-09T21:35:02+11:00September 13th, 2022|

Newell F, Johansson PA, Wilmott JS, Nones K, Lakis V, Pritchard AL, Lo SN, Rawson RV, Kazakoff SH, Colebatch AJ, Koufariotis LT, Ferguson PM, Wood S, Leonard C, Law MH, Brooks KM, Broit N, Palmer JM, Couts KL, Vergara IA, Long GV, Barbour AP, Nieweg OE, Shivalingam B, Robinson WA, Stretch JR, Spillane AJ, Saw RPM, Shannon KF, Thompson JF, Mann GJ, Pearson JV, Scolyer RA, Waddell N, Hayward NK. Cancer Discov. 2022 Sep 13:CD-22-0603. doi: 10.1158/2159-8290.CD-22-0603. Epub ahead of print. PMID: 36098958.

|

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.

2022-10-23T20:07:40+11:00September 10th, 2022|

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzner R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Krepler C, Marreaud S, Suciu S, Robert C.  NEJM Evidence. 2022 Sep 10. doi: 10.1056/EVIDoa2200214. Epub ahead of print.

|

In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.

2022-10-23T19:14:26+11:00September 9th, 2022|

Sahu A, Kose K, Kraehenbuehl L, Byers C, Holland A, Tembo T, Santella A, Alfonso A, Li M, Cordova M, Gill M, Fox C, Gonzalez S, Kumar P, Wang AW, Kurtansky N, Chandrani P, Yin S, Mehta P, Navarrete-Dechent C, Peterson G, King K, Dusza S, Yang N, Liu S, Phillips W, Guitera P, Rossi A, Halpern A, Deng L, Pulitzer M, Marghoob A, Chen CJ, Merghoub T, Rajadhyaksha M. Nat Commun. 2022 Sep 9;13(1):5312. doi: 10.1038/s41467-022-32738-7. PMID: 36085288; PMCID: PMC9463451.

|

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.

2022-10-23T19:53:17+11:00September 1st, 2022|

Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, Versluis JM, Ribero R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV. Nat Med 2022 Sep 22. doi: 10.1038/s41591-022-01965-2. Epub ahead of print.

|

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022.

2022-11-20T10:26:50+11:00August 1st, 2022|

Gauci ML, Aristei C, Becker JC, Blom A, Bataille V, Dreno B, Del Marmol V, Forsea AM, Fargnoli MC, Grob JJ, Gomes F, Hauschild A, Hoeller C, Harwood C, Kelleners-Smeets N, Kaufmann R, Lallas A, Malvehy J, Moreno-Ramirez D, Peris K, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, van Akkooi ACJ, Lorigan P, Garbe C, Lebbé C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer. 2022 Aug;171:203-231. doi: 10.1016/j.ejca.2022.03.043. Epub 2022 Jun 19. PMID: 35732101.

|

Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms.

2022-07-23T17:39:25+10:00December 1st, 2021|

Benton S, Zhao J, Zhang B, Bahrami A, Barnhill RL, Busam K, Cerroni L, Cook MG, de la Fouchardière A, Elder DE, Johansson I, Landman G, Lazar A, LeBoit P, Lowe L, Massi D, Duncan LM, Messina J, Mihic-Probst D, Mihm MC Jr, Piepkorn MW, Schmidt B, Scolyer RA, Shea CR, Tetzlaff MT, Tron VA, Xu X, Yeh I, Yun SJ, Zembowicz A, Gerami P. Am J Surg Pathol. 2021 Dec 1;45(12):1597-1605

|

Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial.

2022-07-23T17:22:11+10:00November 24th, 2021|

Ackermann DM, Dieng M, Medcalf E, Jenkins MC, van Kemenade CH, Janda M, Turner RM, Cust AE, Morton RL, Irwig L, Guitera P, Soyer HP, Mar V, Hersch JK, Low D, Low C, Saw RPM, Scolyer RA, Drabarek D, Espinoza D, Azzi A, Lilleyman AM, Smit AK, Murchie P, Thompson JF, Bell KJL. JAMA Dermatol. (Epub 24 Nov 2021)

|

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

2022-07-23T17:15:22+10:00November 24th, 2021|

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. J Clin Oncol. (Epub 24 Nov 2021)

|

Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis.

2022-07-23T16:44:16+10:00October 21st, 2021|

Zaremba A, Kramer R, De Temple V, Bertram S, Salzmann M, Gesierich A, Reinhardt L, Baroudjian B, Sachse MM, Mechtersheimer G, Johnson DB, Weppler AM, Spain L, Loquai C, Dudda M, Pföhler C, Hepner A, Long GV, Menzies AM, Carlino MS, Lebbé C, Enokida T, Tahara M, Bröckelmann PJ, Eigentler T, Kähler KC, Gutzmer R, Berking C, Ugurel S, Stadtler N, Sucker A, Becker JC, Livingstone E, Meier F, Hassel JC, Schadendorf D, Hanoun M, Heinzerling L, Zimmer L. Front Oncol. (21 Oct 2021)

|

Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.

2022-07-23T20:29:32+10:00October 15th, 2021|

Peri A, Greenstein E, Alon M, Pai JA, Dingjan T, Reich-Zeliger S, Barnea E, Barbolin C, Levy R, Arnedo-Pac C, Kalaora S, Dassa B, Feldmesser E, Shang P, Greenberg P, Levin Y, Benedek G, Levesque MP, Adams DJ, Lotem M, Wilmott JS, Scolyer RA, Jönsson GB, Admon A, Rosenberg SA, Cohen CJ, Niv MY, Lopez-Bigas N, Satpathy AT, Friedman N, Samuels Y. J Clin Invest. 2021 Oct 15;131(20):e129466.

|

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).

2022-07-23T20:20:49+10:00October 8th, 2021|

Lau PKH, Feran B, Smith L, Lasocki A, Molania R, Smith K, Weppler A, Angel C, Kee D, Bhave P, Lee B, Young RJ, Iravani A, Yeang HA, Vergara IA, Kok D, Drummond K, Neeson PJ, Sheppard KE, Papenfuss T, Solomon BJ, Sandhu S, McArthur GA. J Immunother Cancer. (Epub 8 Oct 2021)

|

Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.

2022-07-23T19:23:39+10:00September 8th, 2021|

Haggenmüller S, Maron RC, Hekler A, Utikal JS, Barata C, Barnhill RL, Beltraminelli H, Berking C, Betz-Stablein B, Blum A, Braun SA, Carr R, Combalia M, Fernandez-Figueras MT, Ferrara G, Fraitag S, French LE, Gellrich FF, Ghoreschi K, Goebeler M, Guitera P, Haenssle HA, Haferkamp S, Heinzerling L, Heppt MV, Hilke FJ, Hobelsberger S, Krahl D, Kutzner H, Lallas A, Liopyris K, Llamas-Velasco M, Malvehy J, Meier F, Müller CSL, Navarini AA, Navarrete-Dechent C, Perasole A, Poch G, Podlipnik S, Requena L, Rotemberg VM, Saggini A, Sangueza OP, Santonja C, Schadendorf D, Schilling B, Schlaak M, Schlager JG, Sergon M, Sondermann W, Soyer HP, Starz H, Stolz W, Vale E, Weyers W, Zink A, Krieghoff-Henning E, Kather JN, von Kalle C, Lipka DB, Fröhling S, Hauschild A, Kittler H, Brinker TJ. Eur J Cancer. (Epub 8 Sept 2021)

|

Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition.

2022-07-23T19:11:07+10:00August 25th, 2021|

Grob JJ, Guminski A, Malvehy J, Basset-Seguin N, Bertrand B, Fernandez-Penas P, Kaufmann R, Zalaudek I, Gaudy-Marqueste C, Fargnoli MC, Tagliaferri L, Fertil B, Del Marmol V, Stratigos A, Garbe C, Peris K. J Eur Acad Dermatol Venereol. (Epub 25 Aug 2021)

|

Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy

2022-07-23T18:42:02+10:00August 10th, 2021|

Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson DB, Sullivan RJ, Boland GM. Clin Cancer Res. (Epub 10 Aug 2021)

|

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

2022-07-23T22:00:01+10:00June 9th, 2021|

Brase JC, Walter RFH, Savchenko A, Gusenleitner D, Garrett J, Schimming TT, Váraljai R, Castelletti D, Kim JY, Dakappagari NK, Schultz K, Robert C, Long GV, Nathan PD, Ribas A, Flaherty KT, Karaszewska B, Schachter J, Sucker A, Schmid KW, Zimmer L, Livingstone E, Gasal E, Schadendorf D, Roesch A. Clin Cancer Res. (Epub 9 June 2021)

|

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

2022-07-25T21:12:03+10:00April 30th, 2021|

Jason J Luke, Prof Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Prof Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Prof Muhammad A Khattak, Prof Dirk Schadendorf, Prof Georgina V Long, Paolo A Ascierto, Mario Mandala, Federica De Galitiis, Andrew Haydon, Reinhard Dummer, Prof Jean-Jacques Grob, Caroline Robert, Matteo S Carlino, Peter Mohr, Andrew Poklepovic, Prof Vernon K Sondak, Prof Richard A Scolyer, John M Kirkwood, Ke Chen, Scott J Diede, Sama Ahsan, Nageatte Ibrahim, Prof Alexander M M. Lancet. (30 Apr 2022)

|

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

2022-06-09T10:58:09+10:00February 9th, 2021|

Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman, Alexander C. Huang, Michael T. Tetzlaff, Bart A. van de Wiel, Serigne Lo, Ahmad A. Tarhini, Elizabeth M. Burton, Thomas E. Pennington, Robyn P. M. Saw, Xiaowei Xu, Giorgos C. Karakousis, Paolo A. Ascierto, Andrew J. Spillane, Alexander C. J. van Akkooi, Michael A. Davies, Tara C. Mitchell, Hussein A. Tawbi, Richard A. Scolyer, Jennifer A. Wargo, Christian U. Blank & Georgina V. Long.  Nat Med (2021).

|

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

2022-07-25T22:17:12+10:00February 1st, 2021|

Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, Blank CU, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A. Br J Cancer. 2021 Feb;124(3):574-580.

|

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

2022-11-09T10:00:00+11:00February 11th, 2019|

Tuba N. Gide, Camelia Quek, Alexander M. Menzies, Annie T. Tasker, Ping Shang, Jeff Holst, Jason Madore, Su Yin Lim, Rebecca Velickovic, Matthew Wongchenko, Yibing Yan, Serigne Lo, Matteo S. Carlino, Alexander Guminski, Robyn P.M. Saw, Angel Pang, Helen M. McGuire, Umaimainthan Palendira, John F. Thompson, Helen Rizos, Ines Pires da Silva,
Marcel Batten, Richard A. Scolyer, Georgina V. Long, James S. Wilmott. Cancer Cell Volume 35, Issue 2, P238-255.E6

|

For earlier research papers, prior to 2021, please email digital@melanoma.org.au.  

Go to Top